Annovis Bio, Inc. (ANVS)

Market Cap	97.53M
Revenue (ttm)	n/a
Net Income (ttm)	-24.88M
Shares Out	26.50M
EPS (ttm)	-1.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	603,757
Open	3.690
Previous Close	3.620
Day's Range	3.650 - 3.860
52-Week Range	1.110 - 5.600
Beta	1.49
Analysts	Strong Buy
Price Target	13.50 (+267.85%)
Earnings Date	Nov 12, 2025

About ANVS

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer’s disease, as well as in phase 3 to treat parkinson’s disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzhei...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 29, 2020
• Employees: 15
• Stock Exchange: NYSE
• Ticker Symbol: ANVS
• Website: https://www.annovisbio.com

Analyst Summary

According to 3 analysts, the average rating for ANVS stock is "Strong Buy." The 12-month stock price target is $13.5, which is an increase of 267.85% from the latest price.

Price Target

$13.5

(267.85% upside)

Analyst Consensus: Strong Buy